Shopping Cart
- Remove All
Your shopping cart is currently empty
Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers, thereby blocking downstream pathways. It is applicable for locally advanced or metastatic epithelial tumours, such as non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $538 | In Stock | |
| 5 mg | $1,380 | In Stock | |
| 10 mg | $2,230 | In Stock |
| Description | Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers, thereby blocking downstream pathways. It is applicable for locally advanced or metastatic epithelial tumours, such as non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). |
| In vivo | Izalontamab (5-46 mg/kg, intravenous injection, once every 7 days for a total of 4 doses) demonstrated significant antitumor efficacy in female NOD/SCID mice bearing SW48, FaDu, and KYSE-150 parazacco spilurus subsp. spilurus xenograft tumors. [1] |
| Synonyms | SI-B001, SIB001 |
| Cas No. | 2559704-24-2 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.